Kaliumlosartan/Hydrochloorthiazide Sandoz (Losartan Potassium, Hydrochlorothiazide)

Kaliumlosartan/Hydrochloorthiazide Sandoz combines an ARB and a thiazide diuretic to manage conditions related to high blood pressure.

• Hypertension: reduces systolic and diastolic pressure in essential hypertension.
• Left ventricular hypertrophy: helps decrease cardiac workload associated with prolonged hypertension.
• Diabetic nephropathy with proteinuria: may slow renal function decline when used as part of a comprehensive treatment plan.

• Losartan potassium selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis, decreasing plasma volume, and enhancing the antihypertensive effect of the ARB. The combined actions result in lowered systemic vascular resistance and reduced blood pressure.

Common side effects are usually mild and transient.

Common Side Effects

• Dizziness: feeling light‑headed, especially after the first doses.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: particularly low potassium levels.
• Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects

• Severe dehydration: marked fluid loss requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels.
• Anaphylactic reaction: severe allergic response with rash, swelling, or breathing difficulty.
• Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

Before initiating therapy, several safety considerations are recommended.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: check serum creatinine and eGFR regularly.
• Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics.
• Pregnancy caution: avoid use in pregnancy due to fetal toxicity risk.
• Elderly dosing: start at lower dose and titrate cautiously.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Kaliumlosartan/Hydrochloorthiazide Sandoz may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use can increase renal adverse events.
• Potassium supplements or potassium‑sparing diuretics: risk of hyperkalemia.
• NSAIDs (e.g., ibuprofen): may reduce antihypertensive efficacy and impair renal function.
• Lithium: increased lithium levels and toxicity.
• Dual thiazide therapy: heightened risk of electrolyte disturbances.

Moderate Interactions (Monitor Closely)

• CYP2C9 inhibitors (e.g., fluconazole): may raise losartan plasma concentrations.
• Other antihypertensives: additive blood pressure lowering effect.
• Antidiabetic agents: potential for enhanced hypoglycemia.
• Antacids containing aluminum or magnesium: may affect absorption of losartan.
• Loop diuretics: monitor for excessive diuresis and electrolyte loss.